000			04225nam a2200433 i 4500
988			_aSpringer_BiomedLife_2019
999			_c115919 _d115919 _x1
001			115919
003			ESmaUEC
005			20230110040242.0
006			a||||fo|||| 00| 0
007			cr nn nnnaamaa
008			190724s2019 gw | s |||| 0|eng d
020			_a9783030199661
024	7		_a10.1007/978-3-030-19966-1 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aQP623.5 .M47 _b2019 EB
245	0	4	_aThe mRNA metabolism in human disease _cedited by Luísa Romão
250			_aFirst edition
264		1	_aCham, Switzerland _bSpringer International Publishing _c2019
300			_a1 recurso en línea (IX, 180 páginas) _b18 ilustraciones, 17 ilustraciones a color
336			_aTexto _btxt _2rdacontent
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_atext file _bPDF
490	0		_aAdvances in Experimental Medicine and Biology _x0065-2598 _v1157
490	0		_aBiomedical and Life Sciences (Springer-11642)
505	0		_aPrelims -- Networks of mRNA processing and alternative splicing regulation in health and disease -- The diverse roles of RNA-binding proteins in glioma development -- Nonsense-mediated mRNA decay in development, stress and cancer -- Implication of mRNA degradation disorders on human DISease: focus on DIS3 and DIS3-like enzymes -- Translational regulation by upstream open reading frames and human diseases -- Alternative mechanisms of mRNA translation initiation in cellular stress response and cancer -- RNA therapeutics: how far have we gone? Index.
520	3		_aThe eukaryotic gene expression pathway involves a number of interlinked steps, with messenger RNA (mRNA) being the key intermediate. The precursor mRNA is transcribed from DNA, processed by removal of introns and addition of the cap structure and the poly(A) tail. The mature mRNA is then exported to the cytoplasm where it is translated into protein and finally degraded. In this process, mRNA is associated with RNA-binding proteins forming ribonucleoprotein complexes, whose protein content evolves throughout the lifetime of the mRNA. While the complexity of eukaryotic gene expression allows the production of proteins to be controlled at many levels, it also makes the process vulnerable to errors. Although eukaryotic cells have evolved elaborate mRNA quality control mechanisms that ensure the fidelity of gene expression, some defects are not detected, thus affecting mRNA metabolism. This condition plays a fundamental role in the pathogenesis of several disease processes, such as neurodegeneration and oncogenesis. Besides, exciting recent data have shown that cellular RNAs can be modified post-transcriptionally via dynamic and reversible chemical modifications, the so-called epitranscriptome. These modifications can alter mRNA structure, being able to modulate different steps of the mRNA metabolism that can be associated with various human diseases, such as systemic lupus erythematosus and cancer. This book provides a collection of novel studies and hypotheses aimed to define the pathophysiological consequences of altered mRNA metabolism events in human cells, and is written for a wide spectrum of readers in the field of gene expression regulation. The last chapter highlights how the discovery of disease-causing defects (or modifications) in mRNA can provide a variety of therapeutic targets that can be used for the development of new RNA-based therapeutics. Hopefully, it may also contribute to inspire the drug-developing scientific community. .
650		7	_2embne _aARN _9144940
650		7	_2embne _aMetabolismo _9138638
650		7	_2embne _9140525 _aÁcidos nucleicos
700	1		_aRomão, Luísa _eeditor _4edt _4http://id.loc.gov/vocabulary/relators/edt
776	0	8	_iPrinted edition: _z9783030199654
776	0	8	_iPrinted edition: _z9783030199678
776	0	8	_iPrinted edition: _z9783030199685
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-19966-1 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_aSI _cm _dz _feng _ggw _h0 _b01/2020 _eel _zSI